Synsam invites you to a video presentation of the Year-end report 2025 and a live Q&A session

Synsam AB will publish its Year-end report 2025 on February 20, 2026 at 07:30 CET, accompanied by a CEO comment and a results presentation by CFO Per Hedblom, with live Q&A webcasts in Swedish (09:30 CET) and English (10:30 CET). The Nordic optician group reports approximately SEK 6.9 billion in net sales on a rolling twelve-month basis to September 2025, roughly 4,000 employees and just over 600 stores, and trades on Nasdaq Stockholm (SYNSAM); presentation materials will be available on the company's investor relations website at release time.

Analysis

Market structure: Synsam (SEK 6.9bn LTM sales, ~600 stores) benefits if the market prizes recurring revenue from its subscription offering; direct winners include digital-first eyewear players and lens manufacturers, losers are undifferentiated high-street opticals that compete on price. Competitive dynamics favor players that convert walk-in customers to subscriptions — a 5–10 percentage-point shift in subscription penetration over 12–36 months could raise revenue visibility and support a 10–25% multiple expansion versus peers. Supply/demand looks stable for consumables (lenses/contact lenses) but vulnerable to supplier concentration and FX (SEK vs EUR/DKK) swings; equity and options volatility will spike around Feb 20, with negligible sovereign bond impact.

Risk assessment: Tail risks include consumer-protection regulation on subscription/credit terms, a major supplier disruption (e.g., single-source lens/frame partner), or an earnings miss that triggers double-digit share-price gap; low-probability but material (30–40% downside scenarios). Immediate horizon (days): event-driven volatility around the Feb 20 release; short-term (weeks): guidance digestion and Q&A; long-term (12–36 months): subscription LTV, churn and store lease liabilities drive valuation. Hidden dependencies: churn rate, ARPU by cohort, lease maturities and supplier concentration are the real earnings levers; catalysts are KPI disclosures (subscription penetration, churn, gross margin) and any M&A commentary.

Trade implications: For event capture, options straddles or asymmetric call spreads on SYNSAM.ST are preferred to an outright directional bet; if IV <35% buy a 1-month ATM straddle sized 0.5–1% portfolio, otherwise buy a call spread to limit premium. Relative-value: long SYNSAM.ST (1–3%) vs short HM-B.ST (H&M B, 1–3%) dollar-neutral to isolate eyewear subscription upside versus apparel cyclicality over 1–3 months. Rebalance exposures from general retail into resilient health/consumer staples names if subscription KPIs disappoint.

Contrarian angles: Consensus may under-appreciate subscription LTV — if Synsam sustains <5% monthly churn and ARPU +3–5% YoY, EPS can re-rate by 15–30% over 12–24 months (historical parallel: digital-first eyewear rollouts like Warby Parker). Conversely, the market can over-penalize a single-quarter miss; a disciplined stop-loss (8–12%) on event trades avoids permanent capital loss. Unintended consequences: rapid subscription growth can mask rising upfront CAPEX and receivable financing, which would compress free cash flow despite revenue growth.

Key Decisions for Investors

• Establish a tactical long position in Synsam (SYNSAM.ST) sized 1.5–3.0% of portfolio ahead of the Feb 20 report, targeting a 12–20% upside in 3 months on upside guidance/metrics; place a stop-loss at -8% intraday gap or -12% mark-to-market within 7 days.
• If SYNSAM options implied volatility <35%, buy a 1-month at-the-money straddle (expiry ~Mar 20, 2026) sized to 0.5–1.0% portfolio to capture event-driven move; if IV >35% buy an asymmetric call spread (buy ATM, sell 10–20% OTM) to limit premium outlay.
• Implement a dollar-neutral pair trade: long SYNSAM.ST 1.5% vs short H&M B (HM-B.ST) 1.5% to express subscription/resilience vs discretionary apparel weakness; close by March 31, 2026 or on a catalyst (±5% sales/guidance revision).
• Reduce non-differentiated Nordic retail exposure by 2–4% and redeploy into healthcare/consumer staples over 30–90 days if Synsam misses subscription KPIs (monitor subscription penetration, churn, ARPU; thresholds: churn >8% or ARPU decline >3% are sell signals).